1-(5-氯-2-哌啶基)哌嗪 | 87394-65-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(5-氯-2-哌啶基)哌嗪
• 中文别名: 1-(5-氯哌啶基)哌嗪；1-(5-氯-2-吡啶)-哌嗪
• 英文名称: 1-(5-chloropyridin-2-yl)piperazine
• CAS: 87394-65-8
• 化学式: C₉H₁₂ClN₃
• mdl: MFCD04115049
• 分子量: 197.667
• InChiKey: ZTLOZFLZBKZABP-UHFFFAOYSA-N

物化性质

• 熔点：
  59-61 °C
• 沸点：
  351.5±37.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  按规定使用和贮存的情况下不会分解，并应避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
1-(5-Chloropyridin-2-yl)piperazine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
1-(5-Chloropyridin-2-yl)piperazine
Ingredient name:
CAS number: 87394-65-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H12ClN3
Molecular weight: 197.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(5-氯-2-哌啶基)哌嗪 在 三乙胺 作用下， 以 乙二醇 为溶剂， 生成 6-Chloro-2-[[4-(5-chloropyridin-2-yl)-1-piperazinyl]-methyl]imidazo[1,2-a]pyridine
  参考文献：
  名称：

  Imidazo\x9b1,2-a!pyridines for the treatment of CNS and cardiac diseases

  摘要：

  本发明涉及式（1）的咪唑并[1,2-a]吡啶化合物，它们是多巴胺D-4拮抗剂，可用作抗精神病药物。

  公开号：

  US05912246A1
• 作为产物：
  描述：

  tert-butyl 4-(5-chloropyridin-2-yl)piperazine-1-carboxylate 在 三氟乙酸 、 碳酸氢钠 作用下， 以 MC 、 水 为溶剂， 反应 2.0h， 以99%的产率得到1-(5-氯-2-哌啶基)哌嗪
  参考文献：
  名称：

  [EN] PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME
  [FR] COMPOSÉS DE PICOLINAMIDE ET DE PYRIMIDINE-4-CARBOXAMIDE, LEUR PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT

  摘要：

  公开号：

  WO2011139107A3

文献信息

• Synthesis and Anxiolytic Activity of N-Substituted Cyclic Imides(1R*,2S*,3R*,4S*)-N-(4-(4-(2-Pyrimidinyl)-1-piperazinyl)butyl)-2,3-bicyclo(2.2.1)heptanedicarboximide(Tandospirone) and Related Compounds.
  作者：Kikuo ISHIZUMI、Atsuyuki KOJIMA、Fujio ANTOKU

  DOI：10.1248/cpb.39.2288

  日期：——

  The in vitro binding affinities of these compounds were also examined for 5-HT1A receptor sites. Structure-activity relationships within these series are discussed. One of these compounds, (1R*,2S*,-3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3- bicyclo[2.2.1]heptanedicarboximide (1: tandospirone), was found to be equipotent with buspirone in its anxiolytic activity and more anxio-selective

  合成了一系列带有ω-（4-芳基和4-杂芳基-1-哌嗪基）烷基的环状酰亚胺，并在体内测试其抗焦虑活性。还检查了这些化合物的体外结合亲和力的5-HT1A受体位点。讨论了这些系列中的构效关系。这些化合物之一，（1R *，2S *，-3R *，4S *）-N- [4- [4-（4-嘧啶基）-1-哌嗪基]丁基] -2,3-双环[2.2.1已发现]庚烷二甲酰亚胺（1：tandospirone）与丁螺环酮具有相同的抗焦虑活性，并且比丁螺环酮和地西epa具有更高的选择性。Tandospirone（1）目前正在作为一种选择性抗焦虑药进行临床评估。
• Parallel Solution-Phase Synthesis and General Biological Activity of a Uridine Antibiotic Analog Library
  作者：Omar Moukha-chafiq、Robert C. Reynolds

  DOI：10.1021/co4001452

  日期：2014.5.12

  coupling of the amino terminus of d-phenylalanine methyl ester to the free 5′-carboxylic acid moiety of 33 followed by sodium hydroxide treatment led to carboxylic acid analog 77. Hydrolysis of this material gave analog 78. The intermediate 77 served as the precursor for the preparation of novel dipeptidyl uridine analogs 79–99 through peptide coupling reactions to diverse amine reactants. None of the described

  在 NIH 路线图计划的中试规模库 (PSL) 计划下，以溶液相方式从胺2和羧酸33和77合成了一个包含 94 种尿苷抗生素类似物的小型库。多样醛，磺酰氯，和羧酸反应物套缩合，2，酸介导的水解导致后，向目标化合物3 - 32以良好的收率和高的纯度。同样，用不同的胺和磺胺处理33得到34 – 75。d氨基末端的偶联-苯丙氨酸甲酯到33的游离 5'-羧酸部分，然后用氢氧化钠处理产生羧酸类似物77。该材料的水解得到类似物78。中间77担任该前体为二肽基新颖尿苷类似物的制备79 - 99通过肽偶联到不同的胺反应剂反应。所描述的化合物均未显示出显着的抗癌或抗疟活性。通过 NIH MLPCN 计划提供和报告的初级筛选中的酶和受体，许多样品表现出各种有希望的抑制性、激动剂、拮抗剂或激活剂特性。
• Parallel Solution Phase Synthesis and Preliminary Biological Activity of a 5′-Substituted Cytidine Analog Library
  作者：Omar Moukha-Chafiq、Robert C. Reynolds、Jacob C. Wilson、Timothy S. Snowden

  DOI：10.1021/acscombsci.9b00072

  日期：2019.9.9

  NIH Roadmap Initiative and the Pilot Scale Library (PSL) Program. Reaction core compounds contained -NH2 (2) and -COOH (44 and 93) groups that were coupled to a diversity of reactants in a parallel, solution phase format to produce the target library. The assorted reactants included -NH2, -CHO, -SO2Cl, and -COOH functional groups, and condensation with the intermediate core materials 2 and 44 followed

  通过美国国立卫生研究院路线图计划和中试规模库（PSL）计划的资助，合成了一个由109个成员组成的5'-取代胞苷类似物库。反应核心化合物包含-NH2（2）和-COOH（44和93）基团，这些基团以平行溶液相的形式与多种反应物偶联，生成目标库。所分类的反应物包括-NH 2，-CHO，-SO 2 Cl和-COOH官能团，并且与中间核材料2和44缩合，然后进行酸性水解，以良好的产率和高纯度产生了3-91。d-苯丙氨酸甲酯的氨基末端与44和NaOH处理的游离5'-COOH的连接产生了核心库-COOH前体93。化合物93是我们独特的二肽基胞苷类似物94-114文库的重要组成部分，它通过-COOH基团与众多商业胺的酰胺偶联，然后进行酸性脱保护作用。通过MLPCN程序对完整的最终文库进行的初步筛选显示，在不同的生物学过程中命中数不多。这些命中可以被认为是命中率领先的优化和开发研究的起点。
• Pyrrolo-pyridine derivatives
  申请人：Merck Sharpe & Dohme Ltd.

  公开号：US05432177A1

  公开（公告）日：1995-07-11

  A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those associated with classical neuroleptic drugs.

  一类吡咯并[2,3-b]吡啶衍生物，其在3位被取代的哌嗪甲基基团是大脑内多巴胺受体亚型的拮抗剂，具有对多巴胺D.sub.4受体亚型的选择性亲和力，相比经典的神经阻滞药物，对治疗和/或预防精神分裂症等精神障碍有益，并表现出较少的副作用。
• Piperazine compounds and medicinal use thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：US06455528B1

  公开（公告）日：2002-09-24

  The present invention relates to a piperazine compound of the formula wherein R1 and R2 are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4 and R5 are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6 and R7 are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8 and R9 are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-&agr; production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-&agr; production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-&agr; production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-&agr; mediated diseases.

  本发明涉及一种哌嗪化合物，其化学式为 其中R1和R2分别为氢、卤素、低烷基、低烷氧基、氨基、取代氨基、硝基、羟基或氰基，R3、R4和R5分别为氢、卤素、低烷基、低烷氧基、硝基、氨基、取代氨基或羟基，R6和R7分别为氢、低烷基、受卤素取代的低烷基、芳基烷基、酰基或受卤素取代的低酰基，R8和R9分别为氢或低烷基，Y为低烷基烯基等，环A为苯基、嘧啶基、噻唑基、吡啶基、吡啉基或咪唑基，其药学上可接受的盐及含有这些化合物的药物制剂。本发明的化合物具有优越的TNF-α产生抑制作用和/或IL-10产生促进作用，由于它不含或仅显示对中枢神经系统有显著减少的作用，该化合物可用作高度安全和优越的TNF-α产生抑制剂和/或IL-10产生促进剂，并可用作预防或治疗由异常TNF-α产生引起的各种疾病的药剂，例如可用于治疗可通过IL-10治愈的慢性炎症性疾病、急性炎症性疾病、感染引起的炎症性疾病、自身免疫疾病、过敏性疾病和TNF-α介导的疾病。